Hepatitis C (HCV) infections are prevalent in the United States, with the most common genotype being genotype 1. New treatments are improving treatment outcomes and reducing side effects. Sofosbuvir combined with ribavirin or pegylated interferon/ribavirin achieves high cure rates of over 90% in 12 weeks of treatment. However, the cost of these new treatments is very high, ranging from $80,000 to $150,000. Upcoming interferon-free regimens using combinations of antiviral drugs may achieve cure rates of over 95% with just 6 weeks of treatment.
This document summarizes the convergent stereoselective synthesis of (-)-deoxypukalide, the enantiomer of a degradation product of the natural product pukalide. Key steps include a novel intraannular furan synthesis using a 4-oxopropargylic β-keto ester and silica gel to form a 3-carboxy 2,5-bridged furan in 96% yield. The synthesis features a "furan-last" strategy employing molecular mechanics calculations to direct stereodefining steps. Installation of the embedded butenolide moiety is achieved to complete the total synthesis of (-)-deoxypukalide, which is confirmed by X-
- The study analyzed patient data including various weight measures, renal clearance equations, and pharmacokinetic values for 239 patients receiving vancomycin.
- Total body weight showed a trend toward being the most accurate predictor of vancomycin volume of distribution, while ideal body weight was the least accurate.
- The Cockcroft-Gault equation using adjusted body weight was the method most closely correlated with vancomycin clearance compared to the MDRD and CKD-EPI equations.
This document describes a study evaluating the impact of a pharmacist-managed culture review process in an emergency department (ED). The study found that of 819 ED patients discharged with positive cultures in 2013, 21.2% required follow-up due to inappropriate antibiotic coverage. An ED pharmacist intervened in all of these cases, resulting in antibiotic changes for 56% of patients. The pharmacist-managed culture review process improved antimicrobial therapy and care escalation for 69.5% of ED patients with positive cultures. The study illustrates the value of pharmacists in providing antimicrobial recommendations to optimize therapy for ED patients.
This study aimed to characterize medication and device therapy recommendations from a Chart-Based Collaborative Medication Review (CMR) team to improve care for 641 veterans with congestive heart failure (CHF) managed by primary care providers. The CMR team, comprising a cardiologist, hospitalist and pharmacist, reviewed charts of patients with ejection fractions ≤40% and provided 98 recommendations for 70 patients, with 59% regarding guideline therapies and 13% regarding device therapies. So far, primary care providers accepted 66% of the recommendations, with a median time of 15 days to acceptance. The study aims to evaluate the impact of these recommendations on patient outcomes.
1) Oregon State University pharmacy students have participated annually in a statewide rural health outreach event during spring break since 2008, performing health screenings and patient education.
2) In 2010, 42 students provided services like health screenings, medication counseling, and vaccinations to underserved communities in 12 rural Oregon sites.
3) The program aims to promote wellness, educate patients, serve rural areas with limited access, demonstrate pharmacists' patient care roles, and provide experience for student pharmacists.
This newsletter summarizes events from the American Pharmacists Association Annual Meeting, including awards received by OSU College of Pharmacy students and faculty. It also announces the winning of a national Project CHANCE award by OSU students to start a medication reconciliation project with local health centers. Finally, it provides announcements of upcoming events and scholarship opportunities.
Hepatitis C (HCV) infections are prevalent in the United States, with the most common genotype being genotype 1. New treatments are improving treatment outcomes and reducing side effects. Sofosbuvir combined with ribavirin or pegylated interferon/ribavirin achieves high cure rates of over 90% in 12 weeks of treatment. However, the cost of these new treatments is very high, ranging from $80,000 to $150,000. Upcoming interferon-free regimens using combinations of antiviral drugs may achieve cure rates of over 95% with just 6 weeks of treatment.
This document summarizes the convergent stereoselective synthesis of (-)-deoxypukalide, the enantiomer of a degradation product of the natural product pukalide. Key steps include a novel intraannular furan synthesis using a 4-oxopropargylic β-keto ester and silica gel to form a 3-carboxy 2,5-bridged furan in 96% yield. The synthesis features a "furan-last" strategy employing molecular mechanics calculations to direct stereodefining steps. Installation of the embedded butenolide moiety is achieved to complete the total synthesis of (-)-deoxypukalide, which is confirmed by X-
- The study analyzed patient data including various weight measures, renal clearance equations, and pharmacokinetic values for 239 patients receiving vancomycin.
- Total body weight showed a trend toward being the most accurate predictor of vancomycin volume of distribution, while ideal body weight was the least accurate.
- The Cockcroft-Gault equation using adjusted body weight was the method most closely correlated with vancomycin clearance compared to the MDRD and CKD-EPI equations.
This document describes a study evaluating the impact of a pharmacist-managed culture review process in an emergency department (ED). The study found that of 819 ED patients discharged with positive cultures in 2013, 21.2% required follow-up due to inappropriate antibiotic coverage. An ED pharmacist intervened in all of these cases, resulting in antibiotic changes for 56% of patients. The pharmacist-managed culture review process improved antimicrobial therapy and care escalation for 69.5% of ED patients with positive cultures. The study illustrates the value of pharmacists in providing antimicrobial recommendations to optimize therapy for ED patients.
This study aimed to characterize medication and device therapy recommendations from a Chart-Based Collaborative Medication Review (CMR) team to improve care for 641 veterans with congestive heart failure (CHF) managed by primary care providers. The CMR team, comprising a cardiologist, hospitalist and pharmacist, reviewed charts of patients with ejection fractions ≤40% and provided 98 recommendations for 70 patients, with 59% regarding guideline therapies and 13% regarding device therapies. So far, primary care providers accepted 66% of the recommendations, with a median time of 15 days to acceptance. The study aims to evaluate the impact of these recommendations on patient outcomes.
1) Oregon State University pharmacy students have participated annually in a statewide rural health outreach event during spring break since 2008, performing health screenings and patient education.
2) In 2010, 42 students provided services like health screenings, medication counseling, and vaccinations to underserved communities in 12 rural Oregon sites.
3) The program aims to promote wellness, educate patients, serve rural areas with limited access, demonstrate pharmacists' patient care roles, and provide experience for student pharmacists.
This newsletter summarizes events from the American Pharmacists Association Annual Meeting, including awards received by OSU College of Pharmacy students and faculty. It also announces the winning of a national Project CHANCE award by OSU students to start a medication reconciliation project with local health centers. Finally, it provides announcements of upcoming events and scholarship opportunities.
This document summarizes a medication reconciliation project between a college of pharmacy and local community health centers. It acknowledges those who contributed to the project, including a programmer who designed their database. The project aimed to identify medication errors and improve patient care by having pharmacy students reconcile medications for patients. Students identified duplications and unclear directions. They provided medication lists and schedules to help increase adherence. The project faced some challenges but provided learning opportunities for students and helped expand pharmacists' roles in healthcare. It will continue as a permanent patient outreach program.
Becky Pape, CEO of SLCH, was named a finalist for the prestigious Shirley Ann Munroe Leadership Award from the American Hospital Association for her leadership in building the first Oregon medical school in over a century and developing a health career training center. Pape was also recognized for supporting the hospital's participation in a community health improvement partnership. The award recognizes outstanding leadership from hospital administrators of small or rural hospitals.
An intern at SAGH pharmacy named Elva Van Devender has received two national awards for her achievements in pharmacy. She was named a John Gans Scholar by the American Pharmacist Association for her quality, leadership and vision as a student pharmacist. She has also been chosen as a 2009-2010 recipient of the American Society of Health-System Pharmacy Student Leadership Award. Van Devender has a bachelor's degree in chemistry, a doctorate in chemistry, and has organized several community health fairs focused on underserved populations. She remains humble about her accomplishments and credits her colleagues for their support.
Truvada and raltegravir are the preferred regimen for occupational post-exposure prophylaxis (PEP) for HIV exposure. PEP should be started immediately after exposure and continued for 28 days to reduce the risk of HIV infection. Important follow up includes monitoring for side effects, adherence support, and HIV testing at baseline and over several months to evaluate infection status. Pharmacists play a key role in ensuring appropriate PEP regimens can be obtained and supporting patient adherence for full treatment duration.
A 26-year-old female presented with rapidly progressive memory deficits, psychiatric symptoms, and language disintegration. Standard tests were unremarkable but EEG showed encephalopathy. Serum tested positive for anti-NMDA receptor antibodies on two occasions. Imaging found bilateral ovarian tumors, and pathology confirmed teratomas. First-line treatment with tumor resection, IVIG, and steroids led to rapid improvement. Anti-NMDA receptor encephalitis should be considered in similar presentations, especially in young females, as prompt diagnosis and treatment including tumor removal can lead to good outcomes.
Cystic fibrosis is caused by a defective CFTR gene that codes for a chloride channel protein. This leads to thick, sticky mucus production throughout the body. The mucus clogs lungs and pancreas, causing chronic infection, inflammation, and organ damage. While treatments aim to clear mucus, fight infection, and improve nutrition, lung disease remains the main cause of mortality. New drugs called CFTR modulators target the defective protein and may transform treatment by improving symptoms and slowing disease progression.
This document provides an overview of lupus, a chronic autoimmune disease that can affect multiple organs and tissues. It discusses the epidemiology of lupus, noting it primarily affects women and is more common in certain ethnic groups. The pathogenesis involves a genetic predisposition interacting with environmental triggers that result in an abnormal immune response attacking the body's own tissues. Symptoms and organ involvement can vary widely between patients. Diagnosis is based on meeting several criteria that may include rashes, arthritis, kidney disease, neurological issues, and positive antibody tests. Treatment depends on disease severity and organ involvement, ranging from lifestyle changes to immunosuppressive drugs and corticosteroids. Lupus nephritis, or kidney involvement,
The document lists recipients of awards from the American Society of Health-System Pharmacists for the classes of 2010, 2011, and 2012. It provides brief summaries of each recipient's involvement with their school's student society of health-system pharmacy, leadership positions, internships, volunteer work, research presentations, and awards.
This summary provides the key details from the student e-newsletter:
- Eleven OSU students and four faculty members attended the annual APhA meeting in Washington DC. Nearly 7,000 pharmacists and students attended workshops, exhibitions, and events.
- OSU student Elva Van Devender received an APhA Foundation scholarship at the APhA-ASP awards ceremony, where she was one of only nine students nationally to receive this honor.
- Elva Van Devender also received the 2009-2010 ASHP Student Leadership Award, one of only twelve students in the country to receive this prestigious honor.
The document discusses a presentation given to pharmacists about marijuana. It aims to provide information on the clinical pharmacology, evidence for medical use, adverse effects and drug interactions of marijuana so that pharmacists can educate patients and colleagues. The presentation covers the background of marijuana regulation, cannabinoid pharmacology, types of marijuana drugs available, indications for use, evidence of effectiveness for conditions like pain and nausea, side effects, risks of long-term use and interactions with other drugs.
Kcentra is a 4-factor prothrombin complex concentrate approved for reversing vitamin K antagonist-related major bleeding. It contains factors II, VII, IX, X as well as proteins C and S. Kcentra is more effective than fresh frozen plasma for rapidly reversing warfarin-associated coagulopathies and bleeding within 30 minutes of administration. While there is no antidote for newer oral anticoagulants like dabigatran and rivaroxaban, Kcentra may help manage life-threatening bleeding by generating thrombin. Kcentra administration requires monitoring of coagulation parameters and concomitant vitamin K to prevent rebound coagulopathy.
More Related Content
More from Elva Van Devender, Ph.D., Pharm.D., BCPS
This document summarizes a medication reconciliation project between a college of pharmacy and local community health centers. It acknowledges those who contributed to the project, including a programmer who designed their database. The project aimed to identify medication errors and improve patient care by having pharmacy students reconcile medications for patients. Students identified duplications and unclear directions. They provided medication lists and schedules to help increase adherence. The project faced some challenges but provided learning opportunities for students and helped expand pharmacists' roles in healthcare. It will continue as a permanent patient outreach program.
Becky Pape, CEO of SLCH, was named a finalist for the prestigious Shirley Ann Munroe Leadership Award from the American Hospital Association for her leadership in building the first Oregon medical school in over a century and developing a health career training center. Pape was also recognized for supporting the hospital's participation in a community health improvement partnership. The award recognizes outstanding leadership from hospital administrators of small or rural hospitals.
An intern at SAGH pharmacy named Elva Van Devender has received two national awards for her achievements in pharmacy. She was named a John Gans Scholar by the American Pharmacist Association for her quality, leadership and vision as a student pharmacist. She has also been chosen as a 2009-2010 recipient of the American Society of Health-System Pharmacy Student Leadership Award. Van Devender has a bachelor's degree in chemistry, a doctorate in chemistry, and has organized several community health fairs focused on underserved populations. She remains humble about her accomplishments and credits her colleagues for their support.
Truvada and raltegravir are the preferred regimen for occupational post-exposure prophylaxis (PEP) for HIV exposure. PEP should be started immediately after exposure and continued for 28 days to reduce the risk of HIV infection. Important follow up includes monitoring for side effects, adherence support, and HIV testing at baseline and over several months to evaluate infection status. Pharmacists play a key role in ensuring appropriate PEP regimens can be obtained and supporting patient adherence for full treatment duration.
A 26-year-old female presented with rapidly progressive memory deficits, psychiatric symptoms, and language disintegration. Standard tests were unremarkable but EEG showed encephalopathy. Serum tested positive for anti-NMDA receptor antibodies on two occasions. Imaging found bilateral ovarian tumors, and pathology confirmed teratomas. First-line treatment with tumor resection, IVIG, and steroids led to rapid improvement. Anti-NMDA receptor encephalitis should be considered in similar presentations, especially in young females, as prompt diagnosis and treatment including tumor removal can lead to good outcomes.
Cystic fibrosis is caused by a defective CFTR gene that codes for a chloride channel protein. This leads to thick, sticky mucus production throughout the body. The mucus clogs lungs and pancreas, causing chronic infection, inflammation, and organ damage. While treatments aim to clear mucus, fight infection, and improve nutrition, lung disease remains the main cause of mortality. New drugs called CFTR modulators target the defective protein and may transform treatment by improving symptoms and slowing disease progression.
This document provides an overview of lupus, a chronic autoimmune disease that can affect multiple organs and tissues. It discusses the epidemiology of lupus, noting it primarily affects women and is more common in certain ethnic groups. The pathogenesis involves a genetic predisposition interacting with environmental triggers that result in an abnormal immune response attacking the body's own tissues. Symptoms and organ involvement can vary widely between patients. Diagnosis is based on meeting several criteria that may include rashes, arthritis, kidney disease, neurological issues, and positive antibody tests. Treatment depends on disease severity and organ involvement, ranging from lifestyle changes to immunosuppressive drugs and corticosteroids. Lupus nephritis, or kidney involvement,
The document lists recipients of awards from the American Society of Health-System Pharmacists for the classes of 2010, 2011, and 2012. It provides brief summaries of each recipient's involvement with their school's student society of health-system pharmacy, leadership positions, internships, volunteer work, research presentations, and awards.
This summary provides the key details from the student e-newsletter:
- Eleven OSU students and four faculty members attended the annual APhA meeting in Washington DC. Nearly 7,000 pharmacists and students attended workshops, exhibitions, and events.
- OSU student Elva Van Devender received an APhA Foundation scholarship at the APhA-ASP awards ceremony, where she was one of only nine students nationally to receive this honor.
- Elva Van Devender also received the 2009-2010 ASHP Student Leadership Award, one of only twelve students in the country to receive this prestigious honor.
The document discusses a presentation given to pharmacists about marijuana. It aims to provide information on the clinical pharmacology, evidence for medical use, adverse effects and drug interactions of marijuana so that pharmacists can educate patients and colleagues. The presentation covers the background of marijuana regulation, cannabinoid pharmacology, types of marijuana drugs available, indications for use, evidence of effectiveness for conditions like pain and nausea, side effects, risks of long-term use and interactions with other drugs.
Kcentra is a 4-factor prothrombin complex concentrate approved for reversing vitamin K antagonist-related major bleeding. It contains factors II, VII, IX, X as well as proteins C and S. Kcentra is more effective than fresh frozen plasma for rapidly reversing warfarin-associated coagulopathies and bleeding within 30 minutes of administration. While there is no antidote for newer oral anticoagulants like dabigatran and rivaroxaban, Kcentra may help manage life-threatening bleeding by generating thrombin. Kcentra administration requires monitoring of coagulation parameters and concomitant vitamin K to prevent rebound coagulopathy.
More from Elva Van Devender, Ph.D., Pharm.D., BCPS (13)